CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

CAR T cells
CAR T Cells Derived from Stem Cells Target HIV Tissue Reservoirs in Monkeys
CAR T Cells Derived from Stem Cells Target HIV Tissue Reservoirs in Monkeys
Berly McCoy, PhD | May 25, 2021
Transplanted CAR stem cells persisted long term and showed multilineage engraftment in tissues that harbor HIV.
Engineered Immune Cells Eliminate Brain Cancer in Mice
Engineered Immune Cells Eliminate Brain Cancer in Mice
Brooke Dulka, PhD | May 25, 2021
Researchers developed a new CAR T-cell therapy that targets specific growth factor receptors in glioblastoma to eliminate brain tumors.
Environmental Cues Keep CAR T Cells on Track
Environmental Cues Keep CAR T Cells on Track
Aparna Nathan | May 25, 2021
Pairing CARs with a synthetic receptor makes T cells more lethal tumor killers.
Identifying Antibodies that Target Membrane Proteins in Their Native Conformations
Identifying Antibodies that Target Membrane Proteins in Their Native Conformations
The Scientist Creative Services Team in collaboration with OXGENE | May 10, 2021
A new mammalian display platform enhances antibody discovery for challenging protein targets.
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors 
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors 
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 26, 2021
Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.
Boosting CAR T Cell Therapy for Solid Tumors
Boosting CAR T Cell Therapy for Solid Tumors
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 5, 2021
Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.
Bispecific Antibodies Treat Cancer in Mouse Models
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Immunotherapy Combo Reduces Solid Tumors in Mice
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
Live-cell Imaging
Live-cell Imaging
The Scientist Creative Services Team | Aug 27, 2020
Download this eBook to take a closer look at past efforts, modern challenges, and future advances!
Adoptive Cell Therapy Summit
Adoptive Cell Therapy Summit
The Scientist Creative Services Team | Aug 24, 2020
Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 
Natural Killer Cell Therapies Catch Up to CAR T
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
A Bright Scientific Future
A Bright Scientific Future
Bob Grant | Jan 13, 2020
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Immune Cell Bank Bets on Future CAR T Success
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
T Cell Proliferation Linked to CAR T Responses
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.